In a phase 3, double-blind, randomized, placebo-controlled trial, patients with COPD, a history of ... to control for multiplicity, were moderate or severe exacerbation as assessed in a time ...

AstraZeneca to showcase latest research on comprehensive portfolio and pipeline aimed at transforming respiratory diseases at ATS 2025: Cambridge, UK Wednesday, May 14, 2025, 13:0 ...

Last year, the FDA approved the biologic drug Dupixent to treat uncontrolled eosinophilic COPD. The approval marked a step ...

As chronic obstructive pulmonary disease (COPD) gets worse ... Like the disease itself, flare-ups may range from mild to severe. Your doctor will help you come up with a plan for how to handle ...

All were mild ... (COPD) Lunsekimig is being explored in a broad population of asthma patients, regardless of their inflammation and severity status. The readout of the AIRCULES phase 2 study ...

Sanofi's respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD New phase 2 ... amlitelimab in adults with moderate-to-severe asthma.

Itepekimab expanding into chronic rhinosinusitis along with COPD and bronchiectasis ... 2 results for amlitelimab in adults with moderate-to-severe asthma. Amlitelimab: clinically meaningful ...

New phase 2 data for amlitelimab show efficacy in heterogeneous inflammatory asthma Lunsekimig now targeting chronic rhinosinusitis and COPD in ... patients with moderate-to-severe heterogenous ...

Itepekimab expanding into chronic rhinosinusitis along with COPD and bronchiectasis ... including preliminary phase 2 results for amlitelimab in adults with moderate-to-severe asthma. Amlitelimab: ...

May has just begun, and it's time to turn our attention to the FDA decisions on deck for the coming weeks.So far this year, the U.S. regulatory agency has approved only ...